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Postprandial hyperlipidemia with accumulation of remnant lipoproteins is a common metabolic disturbance associated with
atherosclerosis and vascular dysfunction, particularly during chronic disease states such as obesity, the metabolic syndrome and,
diabetes. Remnant lipoproteins become attached to the vascular wall, where they can penetrate intact endothelium causing foam
cell formation. Postprandial remnant lipoproteins can activate circulating leukocytes, upregulate the expression of endothelial
adhesion molecules, facilitate adhesion and migration of inﬂammatory cells into the subendothelial space, and activate the
complement system. Since humans are postprandial most of the day, the continuous generation of remnants after each meal
may be one of the triggers for the development of atherosclerosis. Modulation of postprandial lipemia by lifestyle changes and
pharmacologicalinterventionscouldresultinafurtherdecreaseofcardiovascularmortalityandmorbidity.Thispaperwillprovide
an update on current concepts concerning the relationship between postprandial lipemia, inﬂammation, vascular function, and
therapeutic options.
1.Introduction
Atherosclerosis is the primary cause of death in the world
[1]. Classical risk factors such as smoking, hypertension,
fasting hyperlipidemia, insulin resistance, increased body fat
mass, and unfavourable body fat distribution are strongly
interrelated and can often be found in one and the same
subject. Subjects with fasting hypertriglyceridemia usually
have elevated postprandial lipids due to the close correlation
of fasting and postprandial triglycerides (TG) [2]. Postpran-
dial lipemia has gained interest because of recent reports
showing that nonfasting TG independently predict the risk
for atherosclerosis [3, 4] and are possibly even stronger
predictors of cardiovascular disease (CVD) than fasting TG
[3, 5].
Atherosclerosisisconsideredalow-gradechronicinﬂam-
matory disease [6], and both the postprandial phase and
chronic disease states such as the metabolic syndrome are
associated with increased inﬂammation. This paper outlines
recent developments in the understanding of postprandial
inﬂammation and its relationship with vascular function,
metabolic diseases, and lifestyle behaviour.
2. Metabolism of PostprandialLipemia
Dietary fat is absorbed in the intestine and secreted into
lymph by enterocytes in TG-rich chylomicrons. Once in
the circulation, chylomicrons rapidly undergo hydrolysis to
produce cholesterol-dense lipoprotein remnants which are
taken up by the liver [7, 8]. After a fatty meal, exoge-
nous fatty acids are delivered to the liver by chylomicron
remnants and may then be reassembled and returned to
the blood in very low-density lipoproteins (VLDL) [9].2 International Journal of Vascular Medicine
The hypertriglyceridemia observed postprandially is due to
raised concentrations of chylomicrons, VLDL, and their
respective remnants, collectively known as triglyceride-rich
lipoproteins (TRLs).
People in the Western world are nonfasting for most of
the day, consequently leading to a continuous challenge of
the endothelium by atherogenic lipoprotein remnants [10,
11]. The exogenous chylomicrons and endogenously pro-
duced VLDL share the same metabolic pathway, for exam-
ple, endothelium-bound lipoprotein lipase (LPL), which
hydrolyzes TG into glycerol and fatty acids. In the postpran-
dial phase, due to limited LPL availability, competition at
the level of this enzyme will occur resulting in accumulation
of TRLs. This competition is most likely when fasting
hypertriglyceridemia is present. The increased levels of free
fatty acids (FFAs) as a result of a hypercaloric diet are
regarded as one of the key etiologic components of the
metabolic syndrome, type 2 diabetes (T2DM), and obesity
[12, 13].
3. Residual Risk of Cardiovascular Disease after
LDL Cholesterol Lowering
Based on results from large clinical trials, lipid management
for reducing the risk for CVD has been typically focused
on reducing LDL-C by statin therapy [14–18]. Despite
aggressive LDL-C lowering by statin therapy, approximately
two-thirds of all CVD events remain. These “residual” events
appear to be independent of the LDL-C and in recent
years have gained momentum as a concept of “residual
risk” of CVD. Interestingly, statins do reduce postprandial
lipemia and also have an eﬀect on complement, but they
do not aﬀect TG suﬃciently to be of clinical relevance
in hypertriglyceridemic conditions [2, 19–22]. Interestingly,
this “residual risk” has been found to be greater for treated
patients with diabetes or the metabolic syndrome than
in untreated patients without these conditions [23, 24].
One could interpret these observations to infer that statin
therapy, resulting in LDL-C lowering, does not necessarily
bring the relative CVD risk in patients suﬀering from
diabetes andmetabolic syndrometo thelevelofnondiabetics
and patients without metabolic syndrome. Consequently,
the current model we propose is that the “residual risk”
hypothesis of atherosclerosis is not just dependent on cir-
culating concentrations of LDL-C but is equally dependent
on remnant lipoprotein concentrations and perturbations
in the arterial vessel wall that inﬂuence the rate of arterial
lipoprotein retention. The potential impact of the “resid-
ual risk” hypothesis is perhaps most appreciated during
conditions of increased atherosclerotic risk. For example,
subjects with insulin resistance, T1DM, or T2DM showed
raisedplasmaconcentrationsoffasting remnantlipoproteins
and an ensuing impairment in postprandial lipoprotein
metabolism [25, 26]. The remnant lipoproteins are able to
penetrate arterial tissue and become entrapped within the
subendothelialspace[27].Ithasalsobeendemonstratedthat
remnant lipoproteins can induce macrophage lipid loading,
which is a hallmark feature of early atherogenesis [28–
30]. Moreover, raised fasting concentrations of apoB48, the
speciﬁc protein of chylomicrons and their remnants [31],
have been shown to be elevated in patients with obesity,
insulin-resistance, and T2DM [32–35]. Numerous studies
have shown that fasting levels of remnant lipoproteins can
predict impaired metabolism of chylomicrons, particularly
in those at risk of CVD [36–38]. Under experimental
conditions, some studies have suggested that the small
LDL particles may have a higher rate of delivery but in
turn eﬄux more readily from arterial tissue compared
to remnant lipoproteins [39, 40]. However, despite many
studies showing atherogenic eﬀects of impaired postprandial
lipemia, it remains uncertain whether lowering postprandial
lipemia would reduce CVD risk or if TG are merely a
marker of other metabolic abnormalities [41]. But it is
certain that postprandial lipemia, obesity, insulin resistance,
inﬂammation, and vascular function and atherogenesis are
closely related with each other.
4.PostprandialLipemiaandVascularIntegrity
Coronary arteries are characterized by tightly apposed
endothelial cells with signiﬁcant expression of tight junction
proteins [42]. In healthy vessels, the coronary endothelium
prevents the diﬀusion of large or hydrophilic molecules,
thereby minimising extravasation of systemically derived
potentially inﬂammatory agents and macromolecules. How-
ever, some lipoprotein transport including remnants of
TRLs occurs across intact and functional endothelium via
nonspeciﬁc transcytotic processes [40]. This phenomenon
is predominantly non-pathogenic, because the lipoproteins
are internalized via receptor processes or passage through
the basal laminae and exit via the vasa vasorum. However,
experimental evidence suggests that prolonged retention of
TRLs as a consequence of binding to extracellular matrices
and proteoglycans can stimulate chemotaxis and activation
of circulating inﬂammatory cells (Figure 1)[ 43].
Dietary-lipotoxicity is a term commonly used to broadly
describe processes leading to end-organ damage following
excess exposure to particular lipids [44]. First identiﬁed in
the context of fat-induced insulin resistance, the process has
since been implicated in a range of chronic diseases and
inﬂammatory disorders. Endothelial cells may be particu-
larly susceptible to the eﬀects of dietary lipids associated
with TRLs because of the signiﬁcant level of lipoprotein
processing that occurs via interaction with hydrolytic lipases
and, thereafter, the constant exposure to plasma fatty acids
and cholesterol. Animal feeding studies have shown that
saturated fatty acids and cholesterol-enriched diets increase
protein oxidation and lipid peroxidation and signiﬁcantly
alter cell membrane phospholipids and lipid raft com-
position, key regulators of inﬂammation [45, 46]. Excess
cholesterol can cause mitochondrial dysfunction and trigger
apoptotic pathways [47]. Other mechanisms for dietary
fat-induced alterations in cell function include stimula-
tion of NADPH-oxidase-derived reactive oxygen species or
modulation of mTOR (mammalian target of rapamycin),International Journal of Vascular Medicine 3
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Figure 1: Concept of the initiation of atherosclerosis by rem-
nant lipoproteins: remnants enter the subendothelial space via
nonspeciﬁc transcytotic processes. This is often a nonpathologic
process, because the remnants leave the subendothelial space
again via the vasa vasorum. However, retention of remnants may
occur in the presence of proteoglycans and excess extracellular
matrices. Remnants can be easily taken up by macrophages, in
contrast to LDL, which need to become modiﬁed ﬁrst. Circulating
remnants themselves also contribute to the presence of suben-
dothelial macrophages. Monocytes can bind and take up remnants,
which stimulates the monocytes to become activated. Subsequently,
activated monocytes express adhesion molecules on the outer
membrane and stimulate the expression of endothelial cellular
adhesion molecules (CAMs), which allows monocytes to home on
the endothelium and migrate into the subendothelial space. Finally,
the macrophages change into highly atherogenic foam cells when
lipid uptake exceeds lipid eﬄux.
a key signal transduction protein that regulates vascular
endothelial fenestration [48]. Many other factors have been
suggested to participate in the generation of oxidative
stress. Paraoxonase 1 (PON-1), a potent antioxidant closely
associatedwithHDL-C,seemstobeakeyplayer[49].During
postprandial lipemia, HDL-C tends to decrease, impairing
the reverse cholesterol transport and reducing the anti-
inﬂammatory properties of HDL-C [50], again providing an
extra atherogenic mechanism for postprandial lipemia.
Commensurate with dietary fat modulation, the particle
phenotype of lipoproteins determines the susceptibility to
subendothelial retention. The heparin sulphate proteogly-
cans that bind apo B lipoproteins may have greater aﬃnity
for TRL remnants because of cooperative apolipoprotein
binding domains principally between apo B and apo E and
exacerbates as a consequence of diabetes [51]. Moreover,
apo E facilitates unabated uptake of remnant lipoproteins by
macrophages via alternate pathways without the requisite of
lipoprotein modiﬁcation such as oxidation [52, 53].
Nitric oxide (NO) is also one of the key players of
endothelium-derived factors, which inﬂuences vasomotion,
permeability, proliferation, and vascular smooth cell migra-
tion [54]. NO-mediated endothelial-dependent vascular
relaxation has been shown to be impaired by remnant
lipoproteins in studies with isolated vessel segments from
rats and pigs in vitro [55]. In human subjects with the
metabolic syndrome, but also in healthy subjects, elevated
fasting and postprandial TG have been related to increased
carotidintima-mediathickness(IMT)[56]andreductionsin
NO-dependent postischemic ﬂow-mediated dilation (FMD)
of the brachial artery [57, 58]. This reduction of FMD cor-
related with TG and FFA concentrations and was reversible
when TG concentrations decreased at the end of the oral
fat loading test [57]. Furthermore, postprandial TRLs have
been shown to induce the expression of leukocyte adhesion
molecules on the endothelium, facilitating recruitment of
inﬂammatory cells [59] and remnant lipoproteins have been
found to activate endothelial cells by upregulating COX-
2 expression and activating intracellular signaling pathways
controlled by nuclear factor-kappaB and mitogen-activated
protein kinases [60].
5. Triglyceride-RichLipoproteins
and Inﬂammation
Many inﬂammatory markers, such as C-reactive protein
(CRP), leukocyte count, and complement component 3
(C3), have been associated with CVD [61–66]. Furthermore,
several studies with animal models showed reduced plaque
formation[67,68]andpreventionofendothelialdysfunction
[69], when adherence of leukocytes to the endothelium
was prevented. These ﬁndings support the theory that
atherogenesis, in part, starts with leukocyte-endothelium
interaction and adherence. Obligatory for this adherence is a
cytokine-controlled sequential upregulation of selectins and
adhesion molecules on activated leukocytes and endothelial
cells [70].
Van Oostrom et al. have shown that postprandially,
when TG and glucose rise, neutrophil counts increase with
concomitant production of pro-inﬂammatory cytokines and
oxidative stress; and that these changes may contribute
to endothelial dysfunction [71, 72]. Furthermore, TG and
glucose are able to induce leukocyte activation, as has been
shown in vitro [73, 74]a n dex vivo in hypertriglyceridemic
patients [75]. In healthy volunteers and in patients with pre-
mature CVD, postprandial lipemia has been associated with
the upregulation of leukocyte activation markers [22, 76].
Fasting leukocytes of patients with CVD have an increased
lipid content when compared to controls, and it has been4 International Journal of Vascular Medicine
suggested that this is due to uptake of chylomicrons [77].
Furthermore, uptake of remnant lipoproteins by primary
h u m a nm o n o c y t e sh a sb e e nd e m o n s t r a t e di ne x p e r i m e n t sin
vitro [74]. Leukocytes are also able to take up retinyl esters,
as markers of intestinally derived TRLs [78]. Recently, we
have shown that apo B binds to neutrophils and monocytes
and that postprandial leukocytes transport dietary fatty
acids [79]. This opens the possibility that direct activation
of leukocytes may occur in the blood by interaction with
chylomicrons and their remnants (Figure 1).
Another inﬂammatory pathway related to CVD and lipid
metabolism is the complement system. The C3/acylation
stimulating protein- (C3/ASP-) system has been recognized
as a regulator of adipose tissue fatty acid metabolism [80].
ASP is identical to the desarginated form of the C3 split-
product C3a (C3a-desArg), which is immunologically inac-
tive. The C3/ASP pathway stimulates re-esteriﬁcation of FFA
into TG in adipocytes, reduces adipocyte FFA production by
inhibiting hormone sensitive lipase and stimulates glucose
uptake by adipocytes, ﬁbroblasts, and muscle cells [80]. C3
is a strong predictor of myocardial infarction [64], and it has
been positively associated to obesity, CVD, insulin resistance,
the metabolic syndrome [81], fasting and postprandial TG,
and hypertension [2, 64]. Complement components have
beenshowntocolocalizewithCRPinatheroscleroticplaques
[82] and complement activation also plays a role in the
induction of tissue damage after myocardial infarction [83].
Moreover, chylomicrons are the strongest in vitro and in vivo
stimulators of adipocyte C3 production via activation of the
alternative complement cascade [66, 84]. A postprandial C3
incrementafterafatmealhasbeenshowninhealthysubjects,
patients with CVD, and patients with familial combined
hyperlipidemia [2, 63, 66]. Moreover, this postprandial
increment has been related to TG and FFA metabolism [85].
6. MetabolicSyndrome and InsulinResistance
in Relation to Atherosclerosis and
PostprandialLipemia
Insulin resistance has also been shown to be associated
with impaired vasodilatation, increased oxidative stress
and increased concentrations of FFAs, vasoconstrictors, cell
adhesion molecules, cytokines, and several other mediators
oflow-gradeinﬂammationandthrombogenesis[86].Insulin
resistance increases the risk for CVD severalfold compared
to the normal population; however, the underlying mech-
anisms are not completely deﬁned [87]. Insulin resistance
often clusters with elevated blood pressure, obesity, central
obesity, elevated TG, and low HDL-C. However, whether
hyperinsulinemia itself is indeed an independent predictor
of CVD has often been debated [87]. A recent meta-
analysis by Ruige et al. showed a weak positive association
between high insulin levels and CVD events [88]. Another
meta-analysis involving 87 studies, which included 951,083
patients based on the deﬁnitions of metabolic syndrome by
the 2001 National Cholesterol Education Program (NCEP)
and 2004 revised National Cholesterol Education Program
(rNCEP) demonstrated a 2-fold increase in cardiovascular
outcomes and a 1.5-fold increase in all-cause mortality in
subjects with the metabolic syndrome [89]. According to
the NHANES III data, subjects with metabolic syndrome
but without diabetes had a signiﬁcantly increased preva-
lence of CVD [90]. However, recently, it was shown that
the metabolic syndrome could not improve prediction of
intima media thickness progression compared to the sum
of its risk components [91]. It is evident that postprandial
lipemia is prevalent during conditions of obesity and insulin
resistance and may contribute to increased progression of
CVD. However, a signiﬁcant clinical dilemma still exists
in diagnosing the early phases of the metabolic syndrome
(i.e., prediabetes) and how this impacts on relative risk of
CVD. In part, this has been impaired by the continued
emphasis on LDL-C, which is often normal during early
T2DM, leading to undetected yet insidious progression of
CVD [92, 93]. Indeed, it is interesting to note that the recent
revision by the IDF (International Diabetes Federation)
has deﬁned the metabolic syndrome independent of LDL-
C concentrations [94]. In general, in clinical practice, the
positive eﬀects of LDL-lowering therapy on atherosclerosis
and CVD are nowadays undisputable. While these eﬀorts
are well documented, much less is known about the clinical
beneﬁts of treating postprandial lipemia, despite increas-
ing evidence supporting a causal role between remnant
lipoproteins and the development of CVD [95]. Clinical
studies have so far failed to provide a deﬁnitive association
between impaired postprandial lipoprotein metabolism and
the very early phases of insulin resistance and corresponding
risk indices. Thus, animal models have to oﬀer further
characterization of the early stages of metabolic syndrome in
order to understand the metabolic and postprandial proﬁle
of this condition. Despite a greater emphasis on the study
of CVD risk in the metabolic syndrome, there remains a
lack of well-characterized prediabetic models in order to
investigate the role of postprandial lipoprotein metabolism
in the development of atherosclerosis.
7. Diet, Lifestyle,Pharmacotherapy, and
PostprandialLipemia
Postprandial hyperlipidemia has many negative eﬀects on
vascular integrity, inﬂammation, and fatty acid metabolism
but can be positively inﬂuenced by diet and lifestyle
behaviour. Since postprandial lipemia is a physiological
response to a fatty meal, it could be predicted that it would
be inﬂuenced by the amount and type of fat in the diet, and
there is strong evidence to support this [96, 97]. However,
in recent years, it has become clear that other lifestyle
factors, including dietary protein, ﬁbers and micronutrients,
alcohol consumption, exercise, and smoking also play a
signiﬁcantroleintheregulationofpostprandiallipemia[96].
Postprandial hyperlipidemia may be a link between lifestyle
choices and the current alarming rise in the incidence
of obesity, insulin resistance, T2DM, and CVD [98]. A
summary of the positive and negative eﬀects of lifestyle
factors and metabolic diseases on postprandial lipemia is
shown in Figure 2.International Journal of Vascular Medicine 5
Postprandiallipemiaisevidentafterafatmealcontaining
>30g fat and the rise in plasma TG is dose dependent
up to about 80g [96, 99]. Since the average content of
Western style meals is 20–40g fat and 3-4 meals/day are
typically consumed, it can be concluded that postprandial
lipemia is likely to be present for 18h/day in the Western
population [100]. A single fatty meal causes changes in
TRL particle characteristics, such as their size, number, and
apolipoprotein composition, which depend on the fatty acid
composition of the food. The most pronounced lipemia
judged by these criteria is caused by a meal containing
saturated fatty acids (SFAs), which are found in high
amounts in animal fat, followed by monounsaturated fatty
acids (MUFA), the main fatty acids in olive oil, with
polyunsaturated fatty acids (PUFA), which are found in
vegetable (n-6 PUFA) and ﬁsh (n-3 PUFA) oils, causing the
leastpronouncedeﬀect[96].n-3PUFAhavealsobeenshown
to cause a lower rise in postprandial lipemia compared to
the other types of fat [96, 101, 102]. While acute studies
provide useful information, changes in dietary habits need
to be sustained in the long term for beneﬁcial eﬀects on
health. Both chronic intake and dietary supplementation of
n-3PUFAforperiodsvaryingfrom4weeksto6monthshave
been shown to decrease postprandial hyperlipidemia due to
decreased production of TRLs [103–106]. The eﬀects of fatty
acids other than n-3 PUFA on postprandial lipemia are less
well deﬁned, but generally, MUFA or n-6 PUFA as compared
to SFA have been found to be more beneﬁcial [96, 107, 108].
In addition to fat, the type of dietary proteins and
carbohydrates may also inﬂuence postprandial lipemia. Lean
red meat, soy protein, casein, and whey protein have all been
associated with a reduced postprandial lipemic response
[96,107,109],ashaveindigestiblecarbohydrates(i.e.,dietary
ﬁber) in the form of oat bran, wheat ﬁber, wheat germ,
or psyllium husk [96, 101, 110]. Digestible carbohydrates,
on the other hand, appear to have little eﬀect [111]e x c e p t
for fructose which may enhance the postprandial lipemic
response if more than 50g per day are consumed [112].
Besides macronutrients like fats, carbohydrate, and pro-
tein, the diet contains micronutrients including vitamins,
carotenoids, plant sterols, and polyphenols found in fruit
and vegetables and in beverages such as green tea and red
wine, and these are believed to contribute to the protective
eﬀect against CVD [113]. Polyphenols in green tea and
strawberries have been reported to reduce postprandial
lipemia in hyperlipidemic individuals [114, 115]. In addi-
tion, micronutrients in olive oil have been found to reduce
postprandial lipemia [116]; however, no evidence for an
eﬀect of plant sterols on postprandial lipemia was found in
a study with patients on lipid lowering therapy [117].
In addition to changing to a healthier diet, weight
loss and increased physical activity are eﬀective lifestyle
interventions which reduce postprandial lipemia [118–120].
Exercise before a fat meal, even if only low-to-moderate
volume, has been found to decrease postprandial lipemia
in many studies [120–125]. Moreover, moderate and high
exercise bouts appear to be equally beneﬁcial [126], and a
recent meta-analysis of 16 studies concluded that exercise
i ns h o r tb o u t si sa se ﬀective as continuous exercise in
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Figure 2: Inﬂuence of metabolic diseases and lifestyle factors
on postprandial lipemia: factors listed in green circles reduce
postprandial lipemia, whereas the factors in red have detrimental
eﬀects on postprandial lipemia.
lowering postprandial blood TG concentrations [127]. Low-
volume exercise, however, has been reported to be ineﬀective
in smokers [128], and Bloomer et al. have also reported
recently that long-term high-volume exercise had no eﬀect
on postprandial lipemia in young, healthy individuals [129].
Combining increased physical activity with dietary changes
such as increased n-3 PUFA intake has been found to have a
synergistic eﬀect in reducing postprandial lipemia in active
individuals [96]. The reduction in postprandial lipemia
causedbyexerciseisbelievedtobeduetoincreasedclearance
of TRLs, which is at least partially mediated by an increase
in LPL activity [96]. However, current evidence suggests
that it is not accompanied by a decrease in the associated
postprandial inﬂammation, as assessed by markers such as C
reactive protein, IL-6, or adhesion molecules [121, 123, 124].
In addition to daily meals and exercise, alcohol and
smoking also inﬂuence postprandial lipemia. A study by
Sharrett et al., which included >600 subjects with or without
CVD, demonstrated that smoking and alcohol consumption
as well as the diet are good predictors of postprandial
lipid levels [100]. Despite considerable evidence that low-to-
moderate alcohol intake protects against CVD [130], both
ethanol and red wine have been shown to cause a marked
increase in postprandial lipemia when added to a test meal
[96, 131]. Habitual smokers also have increased postprandial
lipemia, and this is thought to be due to impaired clearance
of chylomicrons and their remnants [132].
Besides lifestyle interventions, no large improvements
have been made in treating postprandial lipemia with
pharmacotherapy. Statins are highly eﬀective in reducing
LDL cholesterol, but they do not aﬀect TG suﬃciently to6 International Journal of Vascular Medicine
be of clinical relevance in hypertriglyceridemic conditions.
However, rosuvastatin is able to reduce the postprandial
proinﬂammatory and procoagulant changes in subjects with
CVD [22]. In addition, a decrease in hepatic FFA ﬂux has
also been reported [133]. These independent eﬀects from
rosuvastatin may protect against CVD when hyperlipidemia
is present. In contrast to statins, pharmacotherapy with
ﬁbrates is eﬀective in lowering TG concentrations. Despite
hypertriglyceridemia being common in the Western popula-
tion, ﬁbrates are used in only 3.6% of hypertriglyceridemic
subjects [134]. Controversy remains in the eﬀectiveness of
ﬁbrates on cardiovascular morbidity and mortality. Recently,
a large meta-analysis of ﬁbrates with 45,058 participants was
performed[135].Thisstudyshowedamodestbutsigniﬁcant
relative risk reduction of 10% for major cardiovascular
events and 13% reduction in coronary events, but mortality
remained unaltered. While certain drugs are beneﬁcial for
improving insulin resistance and potentially postprandial
lipemia, in speciﬁc groups of patients, the eﬀects on
chylomicron and remnant metabolism may be detrimental.
For example, rosiglitazone increases postprandial accumu-
lation of atherogenic remnants in HIV-infected patients
with lipodystrophy [136]. Therefore, when evaluating the
eﬀects of speciﬁc pharmacotherapeutic interventions on
postprandial lipemia, detailed information on all aspects of
the potentially harmful situations will be needed. At this
stage, there is no data available on comparative studies
regarding lifestyle modiﬁcation versus lipid lowering therapy
on the modulation of postprandial lipemia.
8. Conclusions
A residual risk for CVD remains despite aggressive LDL-C
lowering by statins, which can partly be explained by post-
prandial hyperlipidemia, which leads to several metabolic
dysfunctions and dietary lipotoxicity via diﬀerent several
mechanisms. First of all, TRLs are able to penetrate the
arterial wall leading to endothelial lipid deposits, attraction
of monocytes within the subendothelial space, production
of inﬂammatory markers, and oxidative stress. Secondly,
obesity worsens insulin resistance which further increases
postprandial lipemia, consequently resulting in a vicious
circle. Lifestyle interventions like the type of diet, cessation
of smoking, and weight loss are eﬀective methods to reduce
postprandial lipemia and its related dietary lipotoxicity.
Statins also have a beneﬁcial eﬀect on postprandial lipemia.
However, at this stage, there are no data available comparing
the magnitude of lifestyle interventions with pharmacother-
apy on chylomicron metabolism and reduction of CVD.
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